A phase I/IIa study of STN1014101 ophthalmic solution in healthy adult male volunteers and allergic conjunctivitis patients

A clinical trial of STN1014101 ophthalmic solution in healthy adult male volunteers and allergic conjunctivitis patients for single and repeated dose - Phase I/IIa, clinical pharmacology study, exploratory study -

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250810

Enrollment

Registered

2026-03-13

Start date

2026-06-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Interventions

Instill either STN1014101 ophthalmic solution, placebo ophthalmic solution, or Alesion LX 0.1% ophthalmic solution once daily or twice daily, followed by allergen provocation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - 18 to 65 years of age - Male or Female - Has a positive result for from a Type I allergy test.

Exclusion criteria

Exclusion criteria: - Eye disease other than allergic conjunctivitis is present and requires treatment. - Females who are pregnant, nursing or planning a pregnancy, or anyone of childbearing potential who are not using a reliable method of contraception. - Anyone otherwise considered unsuitable for the study by the investigators

Design outcomes

Primary

Measure	Time frame
Safety, Efficacy (Subjective Ocular Symptom Score and Objective Findings Score)	—

Contacts

Public ContactKoji Oka

Santen pharmaceutical co.,ltd

clinical@santen.co.jp81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026